In 2018, Stevens et al. proved that in the BM of MDS patients with >5% blasts, a distinct clonal population of CD34+/CD123+ stem-like cells with altered bioenergetics dominated by an improved redox potential and nitrogen recycling resides. This evidence concerns the gene CD34 and myelodysplastic syndrome.